Presentation is loading. Please wait.

Presentation is loading. Please wait.

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic.

Published byBambang Susman Modified over 5 years ago

Similar presentations

Presentation on theme: "Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic."— Presentation transcript:

1 Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic Oncology  Volume 13, Issue 3, Pages e45-e48 (March 2018) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Computed tomography scan before and after treatment. A mass approximately 1.8 × 1.2 cm in the right upper lobe (A) and a small nodule in the right lower lobe adjacent to pleura (B) were seen before treatment. After a right lower lobe wedge resection and 3 months of EGFR tyrosine kinase inhibitor treatment, a slight enlargement (to 2.1 × 1.6 cm) of the mass in the right upper lobe (C) and multiple nodules varying in size in the bilateral lung (D) presented. After 2 months of crizotinib therapy targeting ALK rearrangement, the lesions in the two lungs had almost disappeared (E and F). Journal of Thoracic Oncology  , e45-e48DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Microscopic and molecular characteristic of multifocal adenocarcinomas. (A) Three spatially separated regions (a, b, and c) occurred in one slide of the adenocarcinoma lesion (hematoxylin and eosin [HE]; original magnification, ×1.25). (B) Regions a and c showed a solid growth pattern (HE; original magnification, ×100), whereas area b presented with a papillary pattern (HE; original magnification, ×100) (C). Anaplastic lymphoma kinase protein was positively expressed in the solid regions a and c (immunohistochemistry; original magnification, ×100) (D) but not in papillary area b (immunohistochemistry; original magnification, ×100) (E). The break-apart fluorescence (FISH) in situ hybridization assay verified ALK receptor tyrosine kinase gene (ALK) rearrangement in solid regions a and c (FISH; original magnification, ×1000) (F) but not in area b (FISH; original magnification, ×1000) (G). However, no mutations of EGFR were not found in solid regions a and c (H), but a deletion of EGFR exon 19 presented in papillary area b (I) by the amplification refractory mutation system–polymerase chain reaction method. Journal of Thoracic Oncology  , e45-e48DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer  Marcel Wiesweg, MD,

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer  Marcel Wiesweg, MD,
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,
Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Similar presentations

Ads by Google